BACKGROUND: Human saphenous vein (HSV) is the autologous conduit of choice for peripheral vascular reconstruction. Injury during harvest leads to vasospasm and a thrombogenic endoluminal surface. A proteomic transduction approach was developed to prevent vein graft vasospasm and thrombosis. METHODS: Recombinant HSP20 protein linked to the TAT protein transduction domain was generated in a bacterial expression system (TAT-HSP20). The effect of this protein on the inhibition of smooth muscle contraction was determined using rings of rabbit aorta and HSV in a muscle bath. In addition, the effects of TAT-HSP20 on platelet aggregation were determined in vitro using human citrated whole blood. RESULTS: Recombinant TAT-HSP20 inhibited norepinephrine-induced contraction of rabbit aortic and HSV segments. Similarly, TAT-HSP20 induced smooth muscle relaxation in HSV segments precontracted with norepinephrine. In human-citrated whole blood, platelet aggregation was significantly inhibited by TAT-HSP20 in a dose-dependent manner. CONCLUSIONS: The results of this study demonstrate that recombinant TAT-HSP20 inhibits vascular smooth muscle contraction and platelet aggregation. This suggests that HSP20 may be an ideal effector molecule to target as a proteomic approach to enhance early vein graft patency rates by preventing acute vasospasm and thrombosis.
BACKGROUND:Human saphenous vein (HSV) is the autologous conduit of choice for peripheral vascular reconstruction. Injury during harvest leads to vasospasm and a thrombogenic endoluminal surface. A proteomic transduction approach was developed to prevent vein graft vasospasm and thrombosis. METHODS: Recombinant HSP20 protein linked to the TAT protein transduction domain was generated in a bacterial expression system (TAT-HSP20). The effect of this protein on the inhibition of smooth muscle contraction was determined using rings of rabbit aorta and HSV in a muscle bath. In addition, the effects of TAT-HSP20 on platelet aggregation were determined in vitro using human citrated whole blood. RESULTS: Recombinant TAT-HSP20 inhibited norepinephrine-induced contraction of rabbit aortic and HSV segments. Similarly, TAT-HSP20 induced smooth muscle relaxation in HSV segments precontracted with norepinephrine. In human-citrated whole blood, platelet aggregation was significantly inhibited by TAT-HSP20 in a dose-dependent manner. CONCLUSIONS: The results of this study demonstrate that recombinant TAT-HSP20 inhibits vascular smooth muscle contraction and platelet aggregation. This suggests that HSP20 may be an ideal effector molecule to target as a proteomic approach to enhance early vein graft patency rates by preventing acute vasospasm and thrombosis.
Authors: Charles R Flynn; Christopher C Smoke; Elizabeth Furnish; Padmini Komalavilas; Jeffrey Thresher; Zhengping Yi; Lawrence J Mandarino; Colleen M Brophy Journal: Protein Expr Purif Date: 2006-09-12 Impact factor: 1.650
Authors: Catherine M Dreiza; Padmini Komalavilas; Elizabeth J Furnish; Charles R Flynn; Michael R Sheller; Christopher C Smoke; Luciana B Lopes; Colleen M Brophy Journal: Cell Stress Chaperones Date: 2009-07-01 Impact factor: 3.667
Authors: Padmini Komalavilas; Raymond B Penn; Charles R Flynn; Jeffrey Thresher; Luciana B Lopes; Elizabeth J Furnish; Manhong Guo; Manuel A Pallero; Joanne E Murphy-Ullrich; Colleen M Brophy Journal: Am J Physiol Lung Cell Mol Physiol Date: 2007-11-09 Impact factor: 5.464
Authors: Luciana B Lopes; Elizabeth J Furnish; Padmini Komalavilas; Charles R Flynn; Patricia Ashby; Adam Hansen; Daphne P Ly; George P Yang; Michael T Longaker; Alyssa Panitch; Colleen M Brophy Journal: J Invest Dermatol Date: 2008-09-11 Impact factor: 8.551
Authors: B Tedesco; R Cristofani; V Ferrari; M Cozzi; P Rusmini; E Casarotto; M Chierichetti; F Mina; M Galbiati; M Piccolella; V Crippa; A Poletti Journal: Front Mol Biosci Date: 2022-02-25
Authors: Tamara P Martin; Maria P Hortigon-Vinagre; Jane E Findlay; Christina Elliott; Susan Currie; George S Baillie Journal: FEBS Open Bio Date: 2014-10-28 Impact factor: 2.693